BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 2656447)

  • 1. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
    Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
    Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
    Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
    Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
    Miyoshi R; Kito S; Ishida H; Katayama S
    Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.
    Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM
    J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity].
    Herrero MT; Luquín MR; Obeso JA
    Arch Neurobiol (Madr); 1992; 55(4):175-82. PubMed ID: 1417423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saccade responses to dopamine in human MPTP-induced parkinsonism.
    Hotson JR; Langston EB; Langston JW
    Ann Neurol; 1986 Oct; 20(4):456-63. PubMed ID: 3491578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease in 1984: an update.
    Lang AE; Blair RD
    Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
    Matsubara K
    Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites.
    Przedborski S; Jackson-Lewis V; Popilskis S; Kostic V; Levivier M; Fahn S; Cadet JL
    Neurochirurgie; 1991; 37(6):377-82. PubMed ID: 1780015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.